1. Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.
- Author
-
Yixian Wang, Zhan Xu, Kuan-Lin Wu, Liqun Yu, Chenhang Wang, Haoxue Ding, Yang Gao, Han Sun, Yi-Hsuan Wu, Meng Xia, Yuda Chen, and Han Xiao
- Subjects
METASTATIC breast cancer ,PROSTATE cancer patients ,BONE metastasis ,METASTASIS ,CANCER cells ,BONE cells - Abstract
Immunotherapy is a promising approach for treating metastatic breast cancer (MBC), offering new possibilities for therapy. While checkpoint inhibitors have shown great progress in the treatment of metastatic breast cancer, their effectiveness in patients with bone metastases has been disappointing. This lack of efficacy seems to be specific to the bone environment, which exhibits immunosuppressive features. In this study, we elucidate the multiple roles of the sialic acid-binding Ig-like lectin (Siglec)-15/sialic acid glyco-immune checkpoint axis in the bone metastatic niche and explore potential therapeutic strategies targeting this glyco-immune checkpoint. Our research reveals that elevated levels of Siglec-15 in the bone metastatic niche can promote tumor-induced osteoclastogenesis as well as suppress antigen-specific T cell responses. Next, we demonstrate that antibody blockade of the Siglec-15/sialic acid glyco-immune checkpoint axis can act as a potential treatment for breast cancer bone metastasis. By targeting this pathway, we not only aim to treat bone metastasis but also inhibit the spread of metastatic cancer cells from bone lesions to other organs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF